Physician profile
Arnulfo Mansur
NPI 1497756365
$133,749.15
in general payments reported to CMS, 2019-2025
18 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $639 · 2021: $733 · 2022: $1,760 · 2023: $36K · 2024: $83K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $89K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $9,438 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,000 · Travel and Lodging: $2,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $88,602.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,090.00 |
| Food and Beverage | $9,437.95 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,000.00 |
| Travel and Lodging | $2,699.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $121,703.82 | 2019-2025 | Cequa |
| Abbvie INC. | $4,424.36 | 2022-2025 | |
| Alcon Vision LLC | $1,534.50 | 2022-2025 | Simbrinza, Hydrus Microstent, Tryptyr |
| Mallinckrodt Hospital Products INC. | $1,470.51 | 2021-2025 | Acthar |
| Allergan, INC. | $1,275.92 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $817.39 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $700.39 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $568.60 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $462.84 | 2019-2021 | |
| Ivantis, INC | $238.13 | 2020-2021 | |
| Harrow Eye, LLC | $215.42 | 2024-2025 | Vevye |
| Amgen INC. | $125.00 | 2024-2025 | Tepezza |
| Shire North American Group INC | $82.29 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.72 | 2019 | |
| New World Medical,INC. | $31.83 | 2024 | Clearpath, Streamline, Kahook Dual Blade |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $22.95 | 2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $16.46 | 2019 | |
| Biotissue Holdings INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnulfo Mansur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.